Kodiak Sciences Inc.
Kodiak Sciences Inc. (Nasdaq: KOD) is a clinical-stage biopharmaceutical company developing medicines for retinal diseases, including diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration and macular edema associated with inflammation. Its proprietary Antibody Biopolymer Conjugate (ABC)… From the company’s description.
In fiscal 2025, Kodiak Sciences Inc. reported a net loss of $229.97M. Operations used $136.01M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kodiak Sciences Inc. does
In the company’s own words
Kodiak Sciences Inc. (Nasdaq: KOD) is a clinical-stage biopharmaceutical company developing medicines for retinal diseases, including diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration and macular edema associated with inflammation. Its proprietary Antibody Biopolymer Conjugate (ABC) platform underpins three clinical programs: Zenkuda (tarcocimab), an anti-VEGF therapy; KSI-501, which targets IL-6 and VEGF; and KSI-101, a bispecific protein targeting IL-6 and VEGF. The company is also developing an ABCD platform that incorporates small molecules, with programs for glaucoma and geographic atrophy, and VETi, an AI-enabled wearable vision technology. Kodiak retains global rights to its product candidates and aims to develop and commercialize them itself. Its pipeline has no products approved for commercial sale, and it has never generated product-sales revenue. Founded in 2009, the company collaborates with Lonza on its Ursus commercial-scale drug-substance manufacturing facility. Kodiak’s trademarks include Zenkuda and VETi. Its website is www.kodiak.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1468748
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kodiak Sciences Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Kodiak Sciences Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Kodiak Sciences Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kodiak Sciences Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kodiak Sciences Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kodiak Sciences Inc.'s last four quarterly filings that the numbers alone won't show?”